Pharmaceutical Regulatory Affairs Consulting

China and the Asia Pacific region represent significant opportunities for life sciences companies, but accessing these key markets but accessing these key markets demands a deep understanding of regulatory systems and a clear, sound regulatory strategy.

From shifting requirements and language-specific submissions regulatory agencies and regulatory changes, the region’s frameworks present both promise and potential challenges. At Cisema, we help pharmaceutical companies move forward with confidence by offering expert regulatory affairs consulting tailored to China and the wider Asia Pacific region.

Pharmaceutical Regulatory Affairs Consulting
Regulatory Consulting
Regulatory Affairs Consulting

We support your regulatory journey with end-to-end solutions, from early-stage clinical trial applications to post-market lifecycle management. Our services are built on decades of experience, strong local presence, and close engagement with national regulatory authorities. Whether you are preparing for drug application to the NMPA in China or navigating review processes across ASEAN, South Korea, Japan, or Australia, we help reduce approval risk, align with local requirements, and accelerate successful market entry.

Breaking into APAC markets requires more than global documentation, it requires regional adaptation, regulatory intelligence, and operational precision. Our team of experienced regulatory professionals, including expert regulatory consultants, works closely with pharmaceutical and biotech clients to design sound regulatory strategies, ensure compliance, and deliver smoother approval pathways. We simplify your route to product approvals, so you can focus on bringing breakthrough therapies and biologics to patients across the region.

Our Pharmaceutical Regulatory Affairs Services in China & Asia Pacific

Regulatory Strategy & Planning

We assess your product’s regulatory requirements in China and across key Asia Pacific markets and develop submission strategies aligned with local authority expectations. Our customized roadmaps reduce approval delays and help mitigate compliance risks from the outset.

Dossier Preparation & Submission Management

From (Pre-)INDs, CTAs, NDAs, BLAs to DMFs, our regulatory consultants manage the full cycle of pharmaceutical submissions. We handle dossier preparation and formatting to meet both local and global regulatory standards, coordinating directly with regulatory agencies to facilitate a smooth, transparent review process.

CMC Support & GMP Alignment

Chemistry, Manufacturing, and Controls (CMC) compliance is critical for approval. We assist with CMC documentation, GMP expectations, technology transfer, and regulatory gap analysis to meet authority requirements and support manufacturing readiness.

Agency Communication & Representation

We serve as your liaison with regulatory authorities and regulatory agencies in China and across Asia Pacific. From managing pre-submission meetings to handling deficiency responses and advisory consultations, we ensure clear, consistent communication to support timely decision-making.

Labeling & Promotional Compliance

We review and localize your product labeling, packaging, and promotional content to meet country-specific regulatory guidelines. Our support ensures compliance with language, content, and format standards across diverse markets.

Local Representation (Legal Agent / Domestic Responsible Agent)

As required in many jurisdictions, we act as your in-country regulatory representative. Our team manages submissions, post-market compliance, and authority communications, offering peace of mind without the need to establish a local legal entity.

Why Work with Cisema?

Local expertise with global reach

Our bilingual teams bridge international quality standards with local regulations

Proven track record

Over 20 years supporting market approvals and compliance in China and Asia Pacific

End-to-end solutions

From system setup to post-market surveillance, we ensure quality management and regulatory compliance throughout the product lifecycle

Industry breadth

Cross-sector expertise in life sciences, food, veterinary, consumer and industrial goods

Role of a China Agent

Frequently Asked Questions

Ideally, during early development. Early regulatory planning allows for better alignment with local data requirements and smoother submission timelines.

While some systems are harmonizing globally, each APAC country has unique processes, especially around dossier format, language, clinical data, and post-market expectations. We guide you through these distinctions to ensure compliance.

In many cases, yes, with caveats. China and other jurisdictions may require bridging or local studies. We evaluate your evidence and advise on the most efficient approval pathways.

We conduct a root cause analysis and engage with authorities to resolve issues quickly. Our team provides corrective strategies to get your application back on track.

Many jurisdictions, including China, South Korea, and Thailand, require local representation. Cisema acts as your regulatory agent across the region, managing compliance and authority interactions.

Our regulatory affairs experts support a full range of pharmaceutical submissions, from (Pre-)INDs, CTAs, NDAs, BLAs, to DMFs, from small molecules to biologics, and across all stages of development throughout the market lifecycle.

Request a Proposal from Our Pharma Team

Let Cisema help turn your plans into reality.

Angebot anfordern

Explore Related Services

Pharmaceutical Development & Strategy

Drive successful market entry and growth with confidence. Our pharmaceutical consulting experts support biotech and life sciences companies in streamlining drug development, accelerating approvals, and achieving commercialization through tailored strategies, clinical insights, and end-to-end compliance solutions.

Mehr erfahren

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consulting experts help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Mehr erfahren

Pharmacovigilance

Ensure drug safety and regulatory compliance across China and Asia Pacific with confidence. Our pharmacovigilance consulting experts support life sciences companies in managing risks, meeting evolving safety requirements, and maintaining market authorization through end-to-end PV solutions tailored to local regulations.

Mehr erfahren

Quality Management & Compliance

Ensure regulatory excellence across China and Asia Pacific with confidence. Our quality management and compliance experts help life sciences companies strengthen GxP systems, streamline audits, and maintain inspection readiness to safeguard market access and operational performance.

Mehr erfahren

Aktuelle Einblicke

Mehr anzeigen

CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

Explore the latest data on China’s clinical research landscape, including record trial activity, shorter development timelines, and emerging R&D trends.

August 3, 2026
CDE Releases 2025 Annual Report on the Progress of Clinical Trials for New Drug Registration in China

China Targets 65 Drugs in Its 12th National Procurement Round

The 12th national VBP round introduces tighter quality, manufacturing, and IP requirements that pharmaceutical companies must meet to compete.

August 3, 2026
China Targets 65 Drugs in Its 12th National Procurement Round

China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

New NMPA CDE guidelines define CTMP and GTMP boundaries, affecting development strategy, CMC planning, and regulatory engagement in China.

August 3, 2026
China CDE Defines Classification Rules for Cell & Gene Therapy Drugs

China's 2026 Essential Medicines Adds More Innovative Drugs

China's updated National Essential Medicines List expands access to innovative medicines, creating new opportunities and strategic considerations for pharmaceutical companies.

August 3, 2026
China's 2026 Essential Medicines Adds More Innovative Drugs
A middle-aged man with glasses is looking down thoughtfully as he pours medication or pills from a small white bottle with a yellow label into his open palm.

China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications

China's NMPA expands priority review eligibility for chemical API marketing authorization applications, supporting domestic API production and drug supply.

August 3, 2026
China NMPA Expands Priority Review for Chemical API Marketing Authorization Applications
Chemical API Manufacturing

China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services

China's 2026 enforcement priorities expand scrutiny of pharmaceutical sales, procurement, pricing, data security, and compliance across the healthcare sector.

August 3, 2026
China Releases 2026 Anti-Corruption Priorities for Pharmaceutical Sales & Medical Services
Zurück
Zurück

Get in Touch with Our Pharma Consultants

Speak with our pharma consultants to explore how our regulatory affairs services, operational capabilities, and expert guidance can help your organization navigate the region's complex pharmaceutical markets.

Angebot anfordern